How should I switch a patient who is currently taking 55 units of insulin lispro (Humalog) subcutaneously daily to insulin aspart (Novolog) while keeping the same dosing schedule?

Switching from Insulin Lispro to Novolog (Insulin Aspart)

Switch the patient directly from 55 units of insulin lispro to 55 units of insulin aspart (Novolog) using the same dosing schedule—these rapid-acting insulin analogs are bioequivalent and can be converted unit-for-unit. 1

Direct 1:1 Conversion

The FDA label for Novolog explicitly states that "when switching from another insulin to NOVOLOG, a different dosage of NOVOLOG may be needed" but emphasizes close monitoring during the transition 1. However, extensive clinical evidence demonstrates that insulin lispro and insulin aspart are pharmacokinetically and pharmacodynamically equivalent, making a 1:1 conversion appropriate 2, 3.

Key Evidence Supporting Unit-for-Unit Conversion:

• Pharmacokinetic equivalence: Both insulins produce similar serum insulin levels (250-300 pmol/L) at approximately 30 minutes and disappear from serum after approximately 4 hours 3
• Pharmacodynamic equivalence: Direct comparison studies show equivalent blood glucose excursions and postprandial control between the two analogs 2
• Clinical outcomes: Studies demonstrate "indistinguishable" effects on carbohydrate and fat metabolism between insulin aspart and lispro 3

Implementation Steps

1. Start Novolog at 55 units subcutaneously daily using the same timing and schedule as the current lispro regimen
2. Maintain the same injection timing: 5-10 minutes before meals (both insulins have identical timing requirements) 1
3. Increase blood glucose monitoring frequency during the first 1-2 weeks of the switch 1
4. Monitor for hypoglycemia: While both insulins have similar hypoglycemia risk profiles, individual responses can vary 4

Critical Monitoring Points

During the first 2 weeks post-switch:

• Check fasting and pre-meal glucose levels daily
• Monitor 2-hour postprandial glucose levels
• Watch for unexpected hypoglycemia, particularly if the patient has renal or hepatic impairment 1

Dose adjustment indicators:

• If fasting glucose increases >30 mg/dL consistently: consider 10-20% dose increase 5
• If hypoglycemia occurs without clear cause: reduce dose by 10-20% 5

Important Caveats

Mixing considerations: If the patient was mixing lispro with NPH insulin, Novolog can also be mixed with NPH—withdraw Novolog into the syringe first and inject immediately after mixing 1. However, if using an insulin pump, never mix Novolog with any other insulin 1.

Injection site rotation: Continue rotating injection sites within the same region (abdomen, thigh, buttocks, or upper arm) to prevent lipodystrophy 1. Avoid injecting into areas of lipodystrophy as this can cause unpredictable absorption and hyperglycemia.

Cost considerations: While clinically equivalent, verify insurance coverage as formulary preferences may affect out-of-pocket costs for the patient.

Why This Approach Works

The 2025 ADA Standards of Care acknowledge that rapid-acting insulin analogs (including both lispro and aspart) are interchangeable prandial insulin options 5. Multiple head-to-head trials confirm their clinical equivalence 2, 6, 3, with one study explicitly stating both analogs are "equally effective for control of postprandial blood glucose excursions" 2.

The unit-for-unit conversion minimizes disruption to glycemic control while the increased monitoring frequency provides a safety net to catch any individual variation in response.